EUVIMEDEUVIMED entdecken
Crossref

STRATIfy‐PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti‐TNF–treated patient

Carles Iniesta-Navalón iD, Manuel Ríos-Saorín, Lorena Rentero-Redondo, Juan José Gascón-Cánovas, Maria Rocio González-Molina, Isabel Nicolás-De Prado, Rosa Gómez-Espín, Elena Urbieta-Sanz

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Carles Iniesta-Navalón und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Reina Sofia Hospital of Murcia, Murcia, Spain. Hauptthemen laut MEDLINE: Adalimumab, Drug Monitoring, Infliximab, Antirheumatic Agents. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The purpose of this study is to identify risk factors associated with pharmacokinetic failure, defined as immunogenicity or subtherapeutic drug concentrations, in patients treated with infliximab (IFX) or adalimumab (ADA), and to develop a predictive model (STRATIfy‐PK SCORE) to support proactive therapeutic drug monitoring (TDM).

Methods

A retrospective cohort study was conducted in adult patients with immune‐mediated inflammatory diseases receiving IFX or ADA. Pharmacokinetic failure was defined by anti‐drug antibodies or subtherapeutic serum concentrations, based on indication‐specific therapeutic thresholds. Multivariate logistic regression models were developed separately for each drug and outcome. Model performance was assessed using area under the receiver operating characteristic curve (AUC) and calibration plots.

Results

Of 457 patients (298 ADA, 159 IFX), 1035 TDM samples were analysed. Subtherapeutic drug concentrations occurred in 59.7% of patients, and immunogenicity was observed in 18.8%. In IFX‐treated patients, predictors of immunogenicity included prior low induction or maintenance levels, ankylosing spondylitis and rheumatoid arthritis. For ADA, predictors were non‐adherence, prior low maintenance levels, early TDM, monotherapy and rheumatic diagnoses. Predictors of subtherapeutic concentrations included prior low maintenance levels, early TDM, high inflammatory burden, and rheumatoid arthritis for IFX, and prior low maintenance levels, ankylosing spondylitis and early TDM for ADA. Predictive models demonstrated good discriminative performance (AUC 0.795–0.800 for immunogenicity; 0.686–0.700 for subtherapeutic levels) and satisfactory calibration.

Conclusions

STRATIfy‐PK SCORE allows early identification of patients at high risk of pharmacokinetic failure and may support proactive, personalized TDM strategies to improve clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabDrug MonitoringInfliximabAntirheumatic AgentsTumor Necrosis Factor-alphaHumansMaleRetrospective StudiesFemaleMiddle AgedAdultAgedRisk FactorsTreatment FailureArthritis, RheumatoidTumor Necrosis Factor InhibitorsModels, Biological

Stichwörter der Autor:innen

adalimumabanti‐TNF agentsimmunogenicityinfliximabpharmacokinetic failurepredictive modeltherapeutic drug monitoring

Substanzen

AdalimumabInfliximabAntirheumatic AgentsTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Hospital Pharmacy, Reina Sofia Hospital of Murcia, Murcia, Spain.
  • Pharmacokinetics and Applied Pharmacotherapy Group, Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), Murcia, Spain.
  • Department of Pharmacology School of Medicine, University of Murcia, Murcia, 30120, Spain.
  • Department of Public Health, University of Murcia, Murcia, Spain.
  • Department of Rheumatology, Reina Sofia Hospital of Murcia, Murcia, Spain.
  • Department of Gastroenterology, Reina Sofia Hospital of Murcia, Murcia, Spain.

ORCID-Profile: Carles Iniesta-Navalón

Zitieren

APA

Iniesta-Navalón, C., Ríos-Saorín, M., Rentero-Redondo, L., Gascón-Cánovas, J. J., González-Molina, M. R., Prado, I. N., Gómez-Espín, R., & Urbieta-Sanz, E. (2025). STRATIfy‐PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti‐TNF–treated patient. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70346

Vancouver

Iniesta-Navalón C, Ríos-Saorín M, Rentero-Redondo L, Gascón-Cánovas JJ, González-Molina MR, Prado IN, et al. STRATIfy‐PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti‐TNF–treated patient. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70346

BibTeX
@article{IniestaNavaln2025,
  author = {Iniesta-Navalón, Carles and Ríos-Saorín, Manuel and Rentero-Redondo, Lorena and Gascón-Cánovas, Juan José and González-Molina, Maria Rocio and Prado, Isabel Nicolás-De and Gómez-Espín, Rosa and Urbieta-Sanz, Elena},
  title = {STRATIfy‐PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti‐TNF–treated patient},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70346}
}
Kostenlos starten →